SEHK:9969Biotechs
InnoCare Pharma (SEHK:9969) Q4 Profit Surge Challenges Bearish Earnings Narratives
Intro
InnoCare Pharma (SEHK:9969) just closed FY 2025 with fourth quarter revenue of C¥1.3b and net income of C¥706.9m, a sharp step up from the smaller quarterly figures that characterised most of the year. The company has seen quarterly revenue move from C¥311.7m in Q4 2024 to C¥381.3m in Q1 2025, C¥350.2m in Q2, C¥383.9m in Q3 and finally C¥1.3b in Q4, while basic EPS across the year swung between a gain of C¥0.01 in Q1 and losses of C¥0.0396 and C¥0.0188 in Q2 and Q3. This sets up a...